Dr Lukasz Magiera

University of Cambridge

University departments
Cancer Research UK Cambridge Institute

Position: Research Associate
Personal home page:

PubMed journal articles - click here

Research description

A subset of tumoural cells, which is identified by expression of Fibroblast Activation Protein alpha (FAP), possess immunosuppressive properties that protect cancer cells from T cell-mediated elimination. I investigate the origin of those cells and their accumulation at the tumour site as well as their embryonic origin and novel ways of neutralising FAP cell-related immunosuppression.

Research Programme
Pancreatic Cancer
Methods and technologies
Confocal microscopy
Fluorescence microscopy
Imaging
Immunohistochemistry
Microscopy
PCR
Tumour type interests
Pancreas
Keywords

cancer stroma microenvironment immune response immunosuppression

lpm30
Recent publications:
 Retrieving latest data from feed...

Symplectic Elements feed provided by Research Information, University of Cambridge


Key publications

Tumoral immune suppression by macrophages expressing fibroblast activation protein-? and heme oxygenase-1. Arnold JN, Magiera L, Kraman M, Fearon DT. Cancer Immunol Res. 2014 Feb;2(2):121-6. doi: 10.1158/2326-6066.CIR-13-0150. Epub 2013 Nov 18. PMID: 24778275 Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8+ T cell. Thaventhiran JE, Hoffmann A, Magiera L, de la Roche M, Lingel H, Brunner-Weinzierl M, Fearon DT. Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):E2223-9. doi: 10.1073/pnas.1209115109. Epub 2012 Jun 27. PMID: 22745171 Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT. Science. 2010 Nov 5;330(6005):827-30. doi: 10.1126/science.1195300. PMID: 21051638